Skip to main content
. 2022 Nov 18;9:950900. doi: 10.3389/fnut.2022.950900

TABLE 1.

Baseline and 6-and 12-month changes (mean and standard deviation) stratified in the control and intervention groups of the participants on the 17-item questionnaire, physical activity, biomarkers, and anthropometric measurements, lipid profile, carbohydrate metabolism, and hormones. Adjusted for sex and age.

Control group
Intervention group
Control group vs. Intervention group
Baseline 6 month-change 12 month-change Baseline 6 month-change 12 month-change Baseline 6 month-adjusted model 12 month-adjusted model
Diet adherence and physical activity
Mediterranean diet adherence (17-point item score) 7.18 (2.36) 3.03* (3.03) 2.55 + ^ (2.94) 7.52
(2.60)
4.13* (3.27) 3.89^ (3.38) 0.30
(−0.17, 0.77)
1.37 (0.88, 1.86) 1.62 (1.13, 2.12)
Physical activity (MET⋅min/week) 2477 (2132.37) 275.77 (2311.75) 367.91^ (2272.46) 2648 (2216.67) 838.78* (2430.42) 872.23 ^ (2207.52) 150.64
(−269.65, 570.93)
649.28 (233.83, 1064.72) 591.67 (206.63, 976.71)
Lipid profile
Total cholesterol (mg/dL) 218.30 (41.22) −3.69 (31.71) −0.16 (33.93) 221.88 (41.65) −4.50* (32.54) −1.70 (32.66) 3.62
(−4.06, 11.30)
0.69
(−4.95, 6.34)
−0.34
(−6.53, 5.85)
HDL cholesterol (mg/dL) 54.29 (11.06) 0.91 (6.89) −0.13 + (7.06) 52.73 (11.21) 2.53* (7.79) 2.62 ^ (7.83) −1.74
(−3.69, 0.22)
1.35
(−0.10, 2.79)
2.29 (0.84, 3.74)
LDL cholesterol (mg/dL) 133.67 (35.19) −4.17* (25.22) 2.03 + (28.77) 139.22 (38.03) −3.03 (27.71) −0.36 (27.70) 5.67
(−1.45, 12.80)
3.44
(−1.38, 8.26)
−0.41
(−5.74, 4.92)
Triglycerides (mg/dL) 144 [107: 186] −5.93 (55.03) −13.48^ (55.65) 134 [104:182] −13.48* [−38:6] −16^ [−42:10] 0.00
(−0.09, 0.08)
−0.12
(−0.18, −0.07)
−0.08
(−0.14, −0.02)
Remnant cholesterol (mg/dL) 29.13 (10.60) −1.08 (8.66) −1.52^ (8.05) 28.52 (10.88) −3.72* (7.82) −3.03^ (9.49) −0.48
(−2.62, 1.67)
−2.81
(−4.30, −1.33)
−1.78
(−3.43, −0.13)
Blood pressure and anthropometric measurements
Systolic pressure (mmHg) 139.25 (13.46) −2.04* (14.30) −3.64^ (14.61) 140.01 (12.90) −6.38* (13.90) −5.18^ (15.43) 0.63
(−1.92, 3.18)
−3.90
(−6.46, −1.35)
−1.09
(−3.79, 1.61)
Diastolic pressure (mmHg) 74.59 (10.74) −0.81 (11.22) −2.10^ (11.11) 75.59 (9.77) −4.99* (10.20) −4.06^ (10.87) 1.13
(−0.80, 3.05)
−3.39
(−5.24, −1.53)
−1.21
(−3.13, 0.71)
Weight (kg) 88.98 (13.71) −2.66* (3.47) −2.67^ (3.99) 87.54 (13.87) −6.31* (4.09) −7.41 + ^ (4.07) −1.12
(−3.46, 1.21)
−3.74
(−4.46, −3.03)
−4.84
(−5.60, −4.08)
Waist circumference (cm) 111.47 (9.56) −2.81* (3.70) −2.83 ^ (4.48) 110.25 (9.74) −6.21* (4.73) −7.28 + ^ (4.37) −1.10
(−2.84, 0.64)
−3.52
(−4.33, −2.70)
−4.57
(−5.44, −3.70)
Carbohydrate metabolism
HOMA 3.14
(3.18)
−0.30* (1.82) −0.34 ^ (1.52) 2.97
(2.17)
−0.75* (1.24) −0.70^ (1.38) −0.17
(−0.79, 0.45)
−0.49
(−0.83, −0.14)
−0.38
(−0.70, −0.06)
Glucose (mg/dL) 119.90 (33.19) −2.92 (22.11) −0.53 (27.27) 120.86 (31.32) −6.67* (17.69) −4.95^ (21.75) 1.04
(−5.25, 7.33)
−3.58
(−7.39, 0.23)
−4.22
(−9.16, 0.72)
HbA1c (%) 6.40 (1.11) −0.27* (0.72) −0.06 + (0.55) 6.33
(0.84)
−0.33* (0.45) −0.21 + ^ (0.50) −0.07
(−0.30, 0.15)
−0.06
(−0.19, 0.07)
−0.14
(−0.27, −0.02)
Insulin (pg/mL) 351.81 (230.53) −24.19 (160.44) −33.22^ (142.44) 336.79 (189.70) −77.56* (129.63) −79.59^ (131.15) −14.65
(−62.49, 33.19)
−57.09
(−90.06, −24.12)
−49.39
(−79.44, −19.33)
Glucagon (pg/mL) 455.03 (163.32) −36.43* (114.51) −39.24^ (115.95) 446.44 (154.60) −47.00* (128.95) −48.99^ (125.23) −6.35 (−41.12, 28.43) −13.46
(−39.90, 12.98)
−11.33
(−38.03, 15.37)
C-peptide (pg/mL) 1054.99
(522.52)
−68.82*
(303.26)
−89.74^
(313.09)
1066.02
(432.07)
−155.66*
(327.24)
−170.98^
(316.98)
11.15
(−97.34, 119.65)
−83.93
(−149.45, −18.41)
−82.90
(−149.68, −16.12)
GLP_1 (pg/mL) 172.39
(134.29)
−8.33
(81.05)
−12.46
(98.24)
166.78
(120.69)
−9.71
(91.22)
−23.20^ (82.12) −5.75
(−34.43, 22.93)
−4.45
(−22.92, 14.01)
−13.74 −33.43, 5.95)
Hormones and inflammation biomarkers
Ghrelin (pg/mL) 807.38
(415.02)
−30.86
(245.98)
−31.21
(236.83)
831.31
(412.41)
−11.05
(207.24)
5.69
(227.47)
26.33
(−67.05, 119.72)
26.96
(−24.03, 77.95)
40.68
(−12.90, 94.25)
Leptin (pg/mL) 7746.99
(4152.80)
−730.11
(2486.83)
−776.03
(2727.56)
7246.06
(3850.42)
−1020.43
(3141.41)
−1310.85
(2524.41)
−385.77
(−1145.57, 374.04)
−425.74
(−1036.51, 185.04)
−698.56
(−1295.48, −101.64)
PAI_1 (pg/mL) 2631.62
(838.39)
−250.14*
(715.26)
−129.02 + ^
(729.33)
2652.39
(828.08)
−425.63*
(837.60)
−371.54^
(692.88)
29.66
(−158.92, 218.24)
−153.42
(−312.00, 5.16)
−252.41
(−403.90, −100.92)
Resistin (pg/mL) 4625.87
(2138.00)
−286.75*
(1670.16)
−362.79^
(1815.51)
4254.35
(1635.32)
−74.65*
(1343.08)
−12.26 + ^
(1176.19)
−378.91
(−812.86, 55.05)
55.85
(−247.20, 358.89)
151.36
(−160.26, 462.98)
Visfatin (pg/mL) 1309.09
(1620.44)
−302.97*
(1314.76)
−300.98^
(1375.44)
1194.63
(1093.55)
−270.33*
(668.66)
−258.90^
(613.18)
−93.64
(−387.15, 199.87)
−52.22
(−205.86, 101.41)
−47.97
(−214.70, 118.76)
hs-PCR (mg/dL) 0.45
(0.61)
−0.07
(0.81)
−0.13^
(0.47)
0.45
(0.61)
−0.13*
(0.63)
−0.11
(0.81)
0.00
(−0.15, 0.16)
−0.01
(−0.09, 0.08)
0.02
(−0.11, 0.15)

#Median and interquartile range were displayed in non-normal distributed variables *: significant P-value between baseline and 6-month follow-up; + : significant P-value between 6-month follow-up and 12-month follow-up; ^: significant P-value between baseline and 12-month follow-up.